Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,769 total articles

Hudson Technologies Signs Licensing Agreement with Solstice Advanced Materials for the Reclamation and Resale of Patented HFO Refrigerants

Hudson Technologies Signs Licensing Agreement with Solstice Advanced Materials for the Reclamation and Resale of Patented HFO Refrigerants

Hudson Technologies has signed a licensing agreement with Solstice Advanced Materials to reclaim and resell patented HFO refrigerants R-448A and R-449A in the U.S. and Canada. This move enhances Hudson's presence in the commercial refrigeration market amidst regulatory phase-downs of higher GWP refrigerants, aligning with efforts to provide sustain…

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Ltd., listed on Nasdaq as MENS, announced updates on its plant-derived drug candidate MCS®-2, emphasizing its clinical advantages in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The drug has completed multiple Phase III trials in the US and Taiwan with strong safety and efficacy profiles, and ho…

One and One Green Technologies. INC Launches Luzon Copper-Gold Ore Tailings Slag Venture to Address Projected 150,000-Ton Global Copper Supply Deficit

One and One Green Technologies. INC Launches Luzon Copper-Gold Ore Tailings Slag Venture to Address Projected 150,000-Ton Global Copper Supply Deficit

One and One Green Technologies. INC (NASDAQ: YDDL), a licensed hazardous waste recycler in the Philippines, announced a new business venture to recover copper-gold ore tailings slag in Luzon. This strategic initiative targets the projected global copper supply deficit of 150,000 metric tons in 2026 by partnering with local small-scale miners and le…

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

ORIC Pharmaceuticals announced plans to report combination dose optimization data from its Phase 1b trial of rinzimetostat in metastatic castration resistant prostate cancer patients. The presentation will occur during a webcast and conference call on March 31, 2026. This update provides insights into dosing strategies for an investigational allost…

Ocean Power Technologies Secures Order for Fully Integrated WAM-V for an Underwater Research Customer in the Nordics

Ocean Power Technologies Secures Order for Fully Integrated WAM-V for an Underwater Research Customer in the Nordics

Ocean Power Technologies announced securing a contract to deliver a fully integrated WAM-V autonomous surface vehicle to a new underwater research customer in the Nordics. This order marks an expansion of the company's presence in the Nordic region and demonstrates ongoing demand across multiple sectors including defense, surface inspections, and u…

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Glucotrack, Inc. announced significant progress towards filing an Investigational Device Exemption (IDE) with the U.S. FDA in Q2 2026 to initiate a U.S. clinical trial for its implantable continuous blood glucose monitoring system. Following successful first-in-human trials in Brazil and a follow-up study in Australia, the company completed key tri…

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Senti Biosciences announced its fourth quarter and full year 2025 financial results, marking significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory acute myeloid leukemia (AML). The company reported positive preliminary Phase 1 clinical data, received FDA Regenerative Medicine Advanced Therapy designation…

Norwegian Cruise Line Holdings Enters into Employment and Equity Award Agreements with President and CEO

Norwegian Cruise Line Holdings Enters into Employment and Equity Award Agreements with President and CEO

Norwegian Cruise Line Holdings Ltd. announced the appointment of John W. Chidsey as President and CEO, effective February 2026, accompanied by a new employment agreement and a $48 million restricted share unit award designed to incentivize long-term shareholder value creation over four years. The equity award includes performance-based and time-ves…

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Inc., a Nasdaq-listed clinical-stage biotech company, announced the filing of a patent application in India for next-generation psychedelic compounds aimed at treating mental health disorders and addiction. This move expands the company's global intellectual property portfolio and builds on its licensing agreement with Yissum Res…

Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements

Streamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements

Streamex Corp. clarifies and disproves misleading third-party reports about the expiration of lock-up agreements related to its January 2026 financing. The company confirms that the previous lock-ups of certain shares held by co-founders Henry McPhie and Morgan Lekstrom were shorter than reported and that newly agreed voluntary one-year lock-ups ha…

Sportradar Files Its Annual Report on Form 20-F

Sportradar Files Its Annual Report on Form 20-F

Sportradar Group AG, a leading global sports technology company, announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The report is available to investors via the company’s website and SEC filings. Sportradar provides technology and services to sports federations, media, and betting opera…

SFL - Notice of Annual General Meeting 2026

SFL - Notice of Annual General Meeting 2026

SFL Corporation Ltd., a maritime shipping company listed on the NYSE, announced its Annual General Meeting to be held on May 11, 2026, with voting record date set for April 1, 2026. The company highlighted its stable dividend record since 2004 and provided a cautionary statement about risks and uncertainties affecting its business including market …

Aurora Mobile Partners with Soochow Securities to Advance Digital Transformation and Develop Intelligent Financial Services Platform

Aurora Mobile Partners with Soochow Securities to Advance Digital Transformation and Develop Intelligent Financial Services Platform

Aurora Mobile has entered into a strategic partnership with Soochow Securities to integrate its intelligent push notification platform, JPush, into Soochow Securities' 'Dongwu Xiucai' mobile app. This collaboration aims to improve real-time, secure delivery of financial notifications and personalized client communication, advancing Soochow's digita…

Legence Reports Fourth Quarter and Year End 2025 Financial Results

Legence Reports Fourth Quarter and Year End 2025 Financial Results

Legence Corp. reported record quarterly revenues of $737.6 million for Q4 2025, a 34.6% increase year-over-year, driven mainly by organic growth. The company posted a 53% increase in quarterly Adjusted EBITDA and a 49% increase in total backlog and awarded contracts to $3.7 billion. Strategic acquisitions including Bowers and Metrix enhance its mar…

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Autolus Therapeutics reported fourth quarter and full year 2025 financial results highlighted by $74.3 million in net product revenue for their CAR T cell therapy AUCATZYL, approved for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company has launched AUCATZYL in the UK following positive NICE evaluation and expects conti…

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a reduced net loss and operational expenses compared to 2024. The company revealed its decision to explore strategic alternatives, including potential sale, merger, or collaborations to maximize shareholder value. With $57.1 million in cash at year-end, they e…